Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer

Fig. 5

Nintedanib plus paclitaxel and PD-L1 antibody increased median survival in the advanced metastatic EMT-6/CDDP model. Kaplan-Meier survival curve median survival times in terms of days after cell implantation for each group. The triple combination improved median survival significantly compared to paclitaxel (PTX) alone (p = 0.0156) and nintedanib plus PTX therapy (p = 0.0125). All groups n = 8. Log-rank (Mantel Cox) test

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us